RAD-140
Testolone — Selective Androgen Receptor Modulator
01
Overview
RAD-140 (Testolone) is a non-steroidal selective androgen receptor modulator (SARM) developed by Radius Health Inc. originally for breast cancer and muscle wasting indications. It demonstrates high affinity and selectivity for the androgen receptor, showing potent anabolic activity in muscle and bone while minimizing androgenic activity in prostate and sebaceous glands.
02
Mechanism of Action
RAD-140 binds the androgen receptor with Ki of approximately 7 nM, triggering AR-dependent gene expression. Its SARM profile arises from differential co-regulator recruitment compared to testosterone, activating anabolic genes in muscle and bone while being relatively inactive in prostate. It also activates neuroprotective AR signaling in the brain.
03
Research Highlights
Preclinical studies show muscle weight increase equivalent to testosterone at lower doses
Neuroprotection research demonstrates protection against kainate-induced neuronal damage
Phase I trials in ER+/AR+ breast cancer show antitumor activity with acceptable safety
04
Dosage
Administration & Timing
Oral administration (capsule or solution), once daily. Research protocols administer independent of food.
Dosage Guidelines
Cycle Length
8–12 weeks; followed by 4–8 week rest and PCT evaluation in research.
05
Reconstitution
Solvent
Not applicable — orally dosed capsule or solution
Volume
N/A
Concentration
10–20 mg per unit dose
Storage
Store at room temperature (15–25 °C); protect from moisture.
Notes
RAD-140 (Testolone) is a non-steroidal SARM. Preclinical — no approved human use. Monitor lipids and liver enzymes in research.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
RAD-140 is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
RAD-140 Knowledge Graph
Explore how RAD-140 connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
RAD-140 — Common Research Questions
What is RAD-140?
RAD-140 (Testolone) is a non-steroidal selective androgen receptor modulator (SARM) developed by Radius Health Inc. originally for breast cancer and muscle wasting indications. It demonstrates high af... RAD-140 belongs to the Non-Peptide Research research category and is studied for its testolone — selective androgen receptor modulator.
How does RAD-140 work?
RAD-140 binds the androgen receptor with Ki of approximately 7 nM, triggering AR-dependent gene expression. Its SARM profile arises from differential co-regulator recruitment compared to testosterone, activating anabolic genes in muscle and bone while being relatively inactive in prostate. It also activates neuroprotective AR signaling in the brain.
What are the key research benefits of RAD-140?
High anabolic-to-androgenic ratio in research. Skeletal muscle mass increase. Bone density improvement. Neuroprotective effects in research models. Breast cancer (ER+/AR+) research applications. Minimal prostate-stimulating activity.
What is the molecular structure of RAD-140?
RAD-140 is a research compound in the Non-Peptide Research category. Detailed molecular structure data is being compiled. Refer to primary literature for structural analysis.
What does the research say about RAD-140?
Preclinical studies show muscle weight increase equivalent to testosterone at lower doses Neuroprotection research demonstrates protection against kainate-induced neuronal damage Phase I trials in ER+/AR+ breast cancer show antitumor activity with acceptable safety These findings are based on preclinical and clinical research. RAD-140 is a research compound and these studies do not constitute medical advice.
Is RAD-140 FDA approved?
No. RAD-140 is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does RAD-140 belong to?
RAD-140 belongs to the Non-Peptide Research category, which focuses on selective androgen receptor modulators and other novel research compounds studied for their unique pharmacological profiles. You can explore more compounds in this category on the Non-Peptide Research pillar page.
Related Articles
RAD-140 (Testolone): Selective Anabolic Activity
Examining RAD-140's tissue-selective androgen receptor binding and its Phase I breast cancer research.
Cardarine (GW501516): PPARδ and Exercise Mimetics
How Cardarine activates PPARδ to drive fatty acid oxidation and its implications for endurance research.
LGD-4033 (Ligandrol): Phase I Clinical Data
Viking Therapeutics' Phase I trial showing dose-dependent lean mass gains and the VK5211 hip fracture study.
Scientific References
Jayaraman et al. — "Testolone: a SARM for muscle and bone" (J Med Chem, 2009)
Radius Health — Phase I ER+/AR+ breast cancer data, 2018
Preclinical studies show muscle weight increase equivalent to testosterone at lower doses
Neuroprotection research demonstrates protection against kainate-induced neuronal damage
Phase I trials in ER+/AR+ breast cancer show antitumor activity with acceptable safety